Email address,Domain name,Organization,Country,State,City,Postal code,Street,Confidence score,Type,Number of sources,Pattern,First name,Last name,Department,Position,Twitter handle,LinkedIn URL,Phone number,Source 1,Source 2,Source 3,Source 4,Source 5,Source 6,Source 7,Source 8,Source 9,Source 10,Source 11,Source 12,Source 13,Source 14,Source 15,Source 16,Source 17,Source 18,Source 19,Source 20,Source 21,Source 22,Source 23,Source 24,Source 25,Source 26,Source 27,Source 28,Source 29,Source 30
hzhen@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",94,personal,1,{f}{last},Huiling,Zhen,Education,Research Support,"","","",http://ammf.org.uk/ammf-conference-2021/abstracts-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,
egustafson@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",94,personal,4,{f}{last},Erik,Gustafson,,Therapeutic Specialist,"","",+1 612 875 2575,http://ce.mayo.edu/content/incyte-virtual-exhibit-hall-hematology-review-2021,http://ce.mayo.edu/content/incyte-virtual-exhibit-hall-19th-annual-mayo-clinic-hematology-review,http://ce.mayo.edu/node/114978,http://ce.mayo.edu/node/110394,,,,,,,,,,,,,,,,,,,,,,,,,
npatel@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",94,personal,8,{f}{last},Nupur,Patel,,"","","",+1 302 498 5822,http://businesswire.com/news/home/20201104005702/en,http://businesswire.com/news/home/20201213005030/en,http://businesswire.com/news/home/20201029005305/en,http://businesswire.com/news/home/20201230005038/en/4893747/incyte-and-cellenkos-enter-into-global-development-collaboration-agreement-for-ck0804,http://businesswire.com/news/home/20201207005982/nl,http://capitelia.ch/plus-de-40-abstracts-du-portefeuille-doncologie-dincyte-sont-acceptes-pour-presentation-lors-du-62e-congres-annuel-virtuel-de-lash,http://biospace.com/article/releases/incyte-announces-results-of-phase-3-ruxcovid-study-of-ruxolitinib-jakafi-as-a-treatment-for-patients-with-covid-19-associated-cytokine-storm,http://lanotta.com/resumen-mas-de-40-resumenes-de-la-cartera-de-oncologia-de-incyte-han-sido-aceptados-para-su-presentacion-en-la-62-a-reunion-anual-virtual-de-ash,,,,,,,,,,,,,,,,,,,,,
jfridman@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",94,personal,1,{f}{last},Jordan,Fridman,,"","","","",http://ashpublications.org/blood/article/115/15/3109/26879/preclinical-characterization-of-the-selective-jak1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mtanner@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",94,personal,1,{f}{last},Mark,Tanner,,"","","","",http://nice.org.uk/guidance/ta451/chapter/5-implementation,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jantonacci@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",94,personal,13,{f}{last},Jenifer,Antonacci,Management,Senior Director,"","",+1 302 498 7036,http://novumpr.nl/2022/07/19/incyte-kondigt-amerikaanse-fda-goedkeuring-aan-van-opzelura-ruxolitinib-creme-voor-de-behandeling-van-vitiligo,http://novumpr.nl/2021/02/19/incyte-kondigt-acceptatie-en-prioriteitsbeoordeling-aan-van-nda-voor-ruxolitinib-creme-voor-atopische-dermatitis,http://sproutnews.com/national-comprehensive-cancer-networkr-adds-monjuvir-tafasitamab-cxix-to-its-clinical-practice-guidelines-in-oncology-for-b-cell-lymphomas,http://businesswire.com/news/home/20200424005077/fr,http://businesswire.com/news/home/20200417005595/en/incyte-announces-initiation-phase-3-ruxcovid-study,http://biotech-365.com/category/business-wire,http://biotech-365.com/category/business-wire/page/2,http://pharma-zeitung.de/incyte-gibt-annahme-von-nda-mit-vorrangiger-prufun.10860.php,http://businesswire.com/news/home/20191127005495/es,http://biospace.com/article/releases/incyte-supports-the-myeloproliferative-neoplasm-community-in-honor-of-rare-disease-day-2018,http://apnews.com/588f6c12beca482abd368f5d306a5cd0,http://biospace.com/article/releases/in-honor-of-mpn-awareness-day-and-blood-cancer-awareness-month-incyte-debuts-documentary-spotlighting-myeloproliferative-neoplasms-mpns-,http://biospace.com/article/releases/incyte-supports-the-myeloproliferative-neoplasm-mpn-community-during-blood-cancer-awareness-month-,,,,,,,,,,,,,,,,
yzhang@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",94,personal,2,{f}{last},Yan,Zhang,Writing & communication,Communications Director,"","","",http://ascpt.org/portals/28/docs/annual%20meetings/annual%20meeting%20archive/2017%20annual%20meeting/itcw/itcw_yan%20zhang.pdf,http://dmd.aspetjournals.org/content/early/2019/04/22/dmd.118.084053,,,,,,,,,,,,,,,,,,,,,,,,,,,
caccola@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",93,personal,1,{f}{last},Colby,Accola,Operations & logistics,Team Member,"","","",http://incyte.com/portals/0/assets/company%20statements/incyte-2022-ingenuity-awards_1november22.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
gshertzer@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",93,personal,7,{f}{last},Greg,Shertzer,Finance,Associate Director Investor Relations,"","",+1 302 274 4779,http://thedailyreformer.com/2023/07/syndax-and-incyte-announce-positive-topline-results-from-the-pivotal-agave-201-trial-of-axatilimab-in-chronic-graft-versus-host-disease,http://biotech-365.com/author/biotech365/page/2,http://biotech-365.com/author/biotech365/page/3,http://biotech-365.com/category/business-wire/page/4,http://biotech-365.com/author/biotech365,http://biotech-365.com/category/business-wire,http://lanotta.com/resumen-los-datos-de-toda-la-cartera-oncologica-de-incyte-han-sido-aceptados-para-su-presentacion-en-el-encuentro-anual-asco-2023-y-en-el-eha2023-hybrid-congress,,,,,,,,,,,,,,,,,,,,,,
jdahlke@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",93,personal,1,{f}{last},Jenny,Dahlke,,Therapeutic Specialist,"","",+1 612 357 0952,http://ce.mayo.edu/node/110394,,,,,,,,,,,,,,,,,,,,,,,,,,,,
cchiou@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",93,personal,12,{f}{last},Christine,Chiou,Finance,Senior Director Investor Relations,"","",+1 302 274 4773,http://pharmabarometer.de/news/incyte-meldet-52-wochen-daten-aus-dem-phase-3-programm-true-v-zur-evaluierung-von-ruxolitinib-creme-opzelura-bei-patienten-mit-vitiligo,http://novumpr.nl/2022/07/19/incyte-kondigt-amerikaanse-fda-goedkeuring-aan-van-opzelura-ruxolitinib-creme-voor-de-behandeling-van-vitiligo,http://novumpr.nl/2021/02/19/incyte-kondigt-acceptatie-en-prioriteitsbeoordeling-aan-van-nda-voor-ruxolitinib-creme-voor-atopische-dermatitis,http://pharmiweb.com/press-release/2021-01-05/morphosys-and-incyte-announce-the-acceptance-of-the-swissmedic-marketing-authorization-application-f,http://biospace.com/article/releases/morphosys-and-incyte-announce-acceptance-by-health-canada-of-the-new-drug-submission-for-tafasitamab,http://biospace.com/article/releases/incyte-announces-results-of-phase-3-ruxcovid-study-of-ruxolitinib-jakafi-as-a-treatment-for-patients-with-covid-19-associated-cytokine-storm,http://capitelia.ch/incyte-annonce-un-avis-favorable-du-chmp-sur-le-pemigatinib-pour-le-traitement-dadultes-atteints-dun-cholangiocarcinome-localement-avance-ou-metastatique-non-resecable,http://jotup.co/de/node/1128362,http://lanotta.com/resumen-mas-de-40-resumenes-de-la-cartera-de-oncologia-de-incyte-han-sido-aceptados-para-su-presentacion-en-la-62-a-reunion-anual-virtual-de-ash,http://biotech-365.com/category/business-wire/page/2,http://biotech-365.com/author/biotech365,http://biotech-365.com/category/business-wire,,,,,,,,,,,,,,,,,
sharvey@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",93,personal,1,{f}{last},Shane,Harvey,Education,Scientist,"","","",http://metroflow.org/steering-committee,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jzhang@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",93,personal,1,{f}{last},Juan,Zhang,Education,Senior Research Scientist,"","","",http://k-state.edu/wgrc/alumni.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
dshuey@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",93,personal,2,{f}{last},Dana,Shuey,Operations & logistics,Program Chair,"","","",http://medfetch.com/r/285689/27647628,http://medfetch.com/re/285689/27647628,,,,,,,,,,,,,,,,,,,,,,,,,,,
candring@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",92,personal,1,{f}{last},Cathy,Andring,,"","","",+1 904 742 9704,http://ce.mayo.edu/node/116631,,,,,,,,,,,,,,,,,,,,,,,,,,,,
pscherle@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",92,personal,5,{f}{last},Peggy,Scherle,,"","","","",http://jitc.bmj.com/content/2/1/3.altmetrics,http://jitc.bmj.com/content/2/1/3,http://jitc.bmj.com/content/2/1/3.citation-tools,http://jitc.bmj.com/content/2/1/3.responses,http://jitc.bmj.com/content/2/1/3.share,,,,,,,,,,,,,,,,,,,,,,,,
ezawislak@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",92,personal,19,{f}{last},Ela,Zawislak,Writing & communication,Director Public Affairs,"","","",http://businesswire.com/news/home/20200530005019/de,http://ansa.it/sito/notizie/economia/business_wire/news/2020-05-29_12954675.html,http://businesswire.com/news/home/20200520005746/en/incyte-morphosys-announce-validation-european-marketing-authorization,http://thetampanews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://birminghamnews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://onvista.de/news/incyte-und-morphosys-melden-validierung-des-europaeischen-zulassungsantrags-fuer-tafasitamab-361298795,http://businesswire.com/news/home/20200521005393/nl,http://houstonnews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://bostonstar.com/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://pharmiweb.com/press-release/2020-05-14/morphosys-and-incyte-announce-long-term-follow-up-results-from-l-mind-study-of-tafasitamab-in-patien,http://connecticut.statenews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://businesswire.com/news/home/20200520005939/it,http://businesswire.com/news/home/20200521005391/es,http://miamimirror.com/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://atlantaleader.com/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://washingtondcnews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://southcarolina.statenews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://marylandleader.com/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://thelasvegasnews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,,,,,,,,,,
efromm@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",92,personal,6,{f}{last},Erik,Fromm,Medical & health,Medical Director,"","","",http://lif.se/om-lif/medlemmar,http://lif.se/en/members,http://mynewsdesk.com/se/incyte/pressreleases/lovande-ny-behandling-vid-gallgaangscancer-2927227,http://mynewsdesk.com/fi/incyte,http://mynewsdesk.com/se/incyte,http://mynewsdesk.com/no/incyte,,,,,,,,,,,,,,,,,,,,,,,
jhulten@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",92,personal,4,{f}{last},Johan,Hulten,Medical & health,Medical Director,"","","",http://mynewsdesk.com/se/incyte/pressreleases/lovande-ny-behandling-vid-gallgaangscancer-2927227,http://mynewsdesk.com/fi/incyte,http://mynewsdesk.com/se/incyte,http://mynewsdesk.com/no/incyte,,,,,,,,,,,,,,,,,,,,,,,,,
cloveman@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",92,personal,7,{f}{last},Catalina,Loveman,Education,Research And Development,"","",+1 302 498 6171,http://menewswire.blogspot.com/2016/05/incyte-et-ariad-annoncent-un-accord.html,http://businesswire.com/news/home/20191114005002/en/incyte-present-upcoming-investor-conference,http://ir.syros.com/annual-filings/content/0001558370-18-001860/syrs-20171231ex1022a272b.htm,http://businesswire.com/news/home/20181019005376/en,http://businesswire.com/news/home/20191127005648/it,http://biospace.com/article/releases/eli-lilly-release-new-data-from-pivotal-ra-beacon-study-show-significant-improvement-in-patient-reported-outcomes-in-rheumatoid-arthritis-patients-tr,http://ir.syros.com/press-releases/detail/118/incyte-and-syros-announce-global-target-discovery-and,,,,,,,,,,,,,,,,,,,,,,
jklemm@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",92,personal,2,{f}{last},Julie,Klemm,Education,Associate Professor,"","","",http://crablab.stanford.edu/people/julie-klemm,http://crablab.stanford.edu/past-lab-members,,,,,,,,,,,,,,,,,,,,,,,,,,,
ecech@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",91,personal,12,{f}{last},Erica,Cech,Operations & logistics,Production Line,"","",+1 302 274 4324,http://globalny.biz/firmnews/id/238,http://lanotta.com/resumen-incyte-anuncia-la-aprobacion-por-parte-de-la-fda-estadounidense-de-la-crema-opzelura-ruxolitinib-para-el-tratamiento-del-vitiligo,http://pharmabarometer.de/news/incyte-erhaelt-zulassung-der-us-amerikanischen-fda-fuer-opzelura-ruxolitinib-creme-fuer-die-behandlung-von-vitiligo,http://pharmabarometer.de/news/incyte-gibt-vollstaendige-ergebnisse-des-phase-3-programms-true-v-zu-ruxolitinib-creme-opzelura-bei-patienten-mit-vitiligo-bekannt,http://pharmabarometer.de/news/incyte-meldet-52-wochen-daten-aus-dem-phase-3-programm-true-v-zur-evaluierung-von-ruxolitinib-creme-opzelura-bei-patienten-mit-vitiligo,http://pharmabarometer.de/news/incyte-meldet-annahme-und-prioritaere-pruefung-des-snda-antrags-fuer-ruxolitinib-creme-opzelura-als-behandlung-fuer-patienten-mit-vitiligo,http://cinquecolonne.it/incyte-annuncia-autorizzazione-da-parte-dellfda-di-opzelura-ruxolitinib-crema-per-il-trattamento-della-vitiligine.html,http://biotech-365.com/category/business-wire/page/2,http://notibomba.com/resumen-incyte-anuncia-la-aprobacion-por-parte-de-la-fda-estadounidense-de-la-crema-opzelura-ruxolitinib-para-el-tratamiento-del-vitiligo,http://novumpr.nl/2022/07/19/incyte-kondigt-amerikaanse-fda-goedkeuring-aan-van-opzelura-ruxolitinib-creme-voor-de-behandeling-van-vitiligo,http://lanotta.com/resumen-incyte-anuncia-los-datos-de-52-semanas-del-programa-de-fase-3-true-v-que-evalua-ruxolitinib-en-crema-opzelura-en-pacientes-con-vitiligo,http://biotech-365.com/author/biotech365,,,,,,,,,,,,,,,,,
pswain@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",91,personal,2,{f}{last},Paula,Swain,Executive,Executive Vice President Human Resources,"","","",http://h1bdata.com,http://h1bdata.com/page/2,,,,,,,,,,,,,,,,,,,,,,,,,,,
mwalker@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",91,personal,1,{f}{last},Michael,Walker,Medical & health,Medicinal Chemistry,"","","",http://youscribe.com/catalogue/documents/savoirs/science-de-la-nature/mrmc-statistics-tutorial-523448,,,,,,,,,,,,,,,,,,,,,,,,,,,,
tholthaus@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",91,personal,3,{f}{last},Tonya,Holthaus,Sales,Pharmaceutical Sales Specialist,"","",+1 740 404 4229,http://ohiopharmacists.org/aws/ohos/pt/sd/news_article/130340/_parent/layout_details_oraldrugs/false,http://associationdatabase.com/aws/ohos/pt/sd/news_article/130340/_parent/layout_details_oraldrugs/false,http://ohos.org/aws/ohos/pt/sd/news_article/130340/_parent/layout_details_oraldrugs/false,,,,,,,,,,,,,,,,,,,,,,,,,,
awilliamson@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",91,personal,1,{f}{last},Anne,Williamson,Writing & communication,Editor In Chief,"","","",http://lehmannlab.med.nyu.edu/content/alumni-0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
scowles@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",91,personal,2,{f}{last},Sid,Cowles,,Senior Scientist,"","","",http://sunmanagers.cs.toronto.edu/1999/0611.html,http://esa-ecophys.org/member99.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,
kgriffiths@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",90,personal,8,{f}{last},,,,,,,,http://checkorphan.org/news/incyte-announces-fda-approval-of-jakafi-ruxolitinib-for-treatment-of-chronic-graft-versus-host-disease-gvhd,http://checkorphan.org/news/incyte-announces-fda-approval-of-jakafi-ruxolitinib-for-treatment-of-chronic-graft-versus-host-disease-gvhd-2,http://incyte.com/portals/0/assets/company%20statements/final_iia_company%20statement.pdf,http://internationalworldofbusiness.com/incyte-provides-regulatory-update-on-ruxolitinib-extended-release-tablets,http://pharmabarometer.de/news/incyte-legt-aktualisierung-zum-regulatorischen-stand-von-ruxolitinib-tabletten-mit-langzeitwirkung-vor,http://biotech-365.com/author/biotech365,http://biotech-365.com/author/biotech365/page/2,http://biotech-365.com/category/business-wire/page/2,,,,,,,,,,,,,,,,,,,,,
eumedinfo@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",90,generic,30,{f}{last},,,Support,,,,,http://facingourrisk.com/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum,http://facingourrisk.com/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum/printable,http://medicines.org.uk/emc/product/13003/smpc,http://incyte.com/portals/0/assets/company%20statements/incy_corpstmt_whoalert_final_3may2019.pdf,http://incyte.com/portals/0/assets/compliance%20and%20transparency/incyte-code-of-business-conduct.pdf,http://incyte.com/what-we-do/portfolio/covid-19,http://meet-incyte.de/impressum,http://cmladvocates.net/2019/02/01/falsified-iclusig-traded-globally-discovered-in-turkey-switzerland-argentina-and-internet-sales-with-uk-ireland-product-batch-numbers-pr072875-45mg-and-25a19e09-15mg,http://medicines.org.uk/emc/company/3248,http://pemazyre.dk/privacy-policy,http://pemazyre.se/hcp/adverse-event,http://pemazyre.se/adverse-event,http://incyte.ch/en,http://incyte.ch/fr,http://incyte.com/contact-us/medical-information,http://incyte.es,http://incyte.ch,http://pro.medicin.dk/adresser/medicinvirksomheder/10564,http://ponatinib.nl,http://incyte.it,http://incyte.com/contact-us,http://vidal.fr/medicaments/iclusig-15-mg-cp-pellic-131894.html,http://felleskatalogen.no/medisin/firmaer/incyte-584802-incyte-biosciences-nordic-ab-629957,http://incyte.nl,http://incyte.pt,http://incyte.jp/contact-us/medical-information,http://pharmacafennica.fi/spc/2946333,http://min.medicin.dk/adresser/medicinvirksomheder/10564,http://incyteglobalmedicalinformation.com/contact-us.aspx,http://incyteglobalmedicalinformation.com/report-adverse-event.aspx
globalmedinfo@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",90,generic,23,{f}{last},,,Support,,,,,http://incyte.com/covid-19,http://incyte.com/portals/0/assets/compliance%20and%20transparency/global_policy%20on%20expanded%20access_compassionate%20use.pdf,http://incyte.com/what-we-do/portfolio/covid-19,http://wcgclinical.com/wp-content/uploads/2022/03/balancing-new-with-common-recruitment-tactics.pdf,http://farmasiindustri.com/industri/list-of-pharmaceutical-manufacturer-in-united-states-of-america-part-4.html,http://incyte.com/contact-us/medical-information,http://bcan.org/clinicaltrials/incb099318-in-participants-with-advanced-solid-tumors,http://clinicaltrials.gov/ct2/show/nct03656536,http://idealmedhealth.com/oncology-drugs-companies,http://clinicaltrials.gov/ct2/show/nct04242199,http://clinicaltrials.gov/ct2/show/study/nct03656536,http://incyte.com/contact-us,http://ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002499-pip02-19,http://clinicaltrials.gov/ct2/show/nct03538028,http://incyte.jp/contact-us/medical-information,http://vrfoundation.org/trials/incyte-ruxolitinib-cream-true-v2,http://vrfoundation.org/trials/incyte-ruxolitinib-cream,http://ema.europa.eu/en/medicines/human/orphan-designations/eu309716,http://ema.europa.eu/en/medicines/human/orphan-designations/eu309715,http://ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001186-pip01-11-m02,http://ema.europa.eu/medicines/human/orphan-designations/eu309716,http://cholangiocarcinoma.org/db/topic/an-open-label-safety-and-tolerability-study-of-incb062079-in-subjects,http://incyte.nl,,,,,,
mbooth@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",90,personal,30,{f}{last},,,Writing & communication,Journalist,,,,http://pressecontrol.de/2020/01/13/morphosys-und-incyte-unterzeichnen-globalen-kollaborations-und-lizenzvertrag-fuer-tafasitamab,http://biospace.com/article/releases/morphosys-and-incyte-announce-acceptance-by-health-canada-of-the-new-drug-submission-for-tafasitamab,http://pharmabarometer.de/news/incyte-meldet-positive-aktualisierte-ergebnisse-der-phase-2-studie-zu-pemigatinib-bei-patienten-mit-bereits-behandeltem-fortgeschrittenem-cholangiokarzinom,http://minelistings.com/mine-news/fda-advisory-committee-recommends-the-approval-of-baricitinib-2mg-but-not-4mg-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis,http://biospace.com/news/eli-lilly-release-new-analyses-of-phase-3-trials/439061,http://jotup.co/de/node/1128362,http://qlifepro.com/press/20160516-19-27093/de-ma-incyte-corporation-2,http://ir.syros.com/press-releases/detail/118/incyte-and-syros-announce-global-target-discovery-and,http://pharmiweb.com/press-release/2021-01-05/morphosys-and-incyte-announce-the-acceptance-of-the-swissmedic-marketing-authorization-application-f,http://menewswire.blogspot.com/2016/05/incyte-et-ariad-annoncent-un-accord.html,http://pharmiweb.com/press-release/2020-05-14/morphosys-and-incyte-announce-long-term-follow-up-results-from-l-mind-study-of-tafasitamab-in-patien,http://biospace.com/article/fda-approves-olumiant-baricitinib-2-mg-tablets-for-the-treatment-of-adults-with-moderately-to-severely-active-rheumatoid-arthritis,http://thetampanews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://lanotta.com/resumen-mas-de-40-resumenes-de-la-cartera-de-oncologia-de-incyte-han-sido-aceptados-para-su-presentacion-en-la-62-a-reunion-anual-virtual-de-ash,http://pharma-zeitung.de/daten-aus-dem-onkologieportfolio-von-incyte-werden.10632.php,http://birminghamnews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://incyte.com/portals/0/assets/company%20statements/jaci_zhou%20iir%20publication_5.26.20%20vfinal.pdf,http://pharma-zeitung.de/incyte-gibt-annahme-von-nda-mit-vorrangiger-prufun.10860.php,http://washingtondcnews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://ansa.it/sito/notizie/economia/business_wire/news/2020-05-29_12954675.html,http://onvista.de/news/incyte-und-morphosys-melden-validierung-des-europaeischen-zulassungsantrags-fuer-tafasitamab-361298795,http://houstonnews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://epicos.com/article/162807/lilly-present-new-data-olumiantr-baricitinib-and-taltzr-ixekizumab-european-academy,http://biospace.com/article/releases/lilly-announces-top-line-phase-3-results-for-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis,http://bostonstar.com/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://atlantaleader.com/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab,http://businesswire.com/news/home/20201104005702/en,http://businesswire.com/news/home/20201207005244/en,http://businesswire.com/news/home/20210119005004/en,http://thelasvegasnews.net/news/265158680/morphosys-and-incyte-announce-the-validation-of-the-european-marketing-authorization-application-for-tafasitamab
medinfo@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",90,generic,30,{f}{last},,,Support,,,,,http://facingourrisk.com/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum,http://facingourrisk.com/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum/printable,http://incytemi.com/pipeline,http://incytemi.com/pipeline/mpns-and-gvhd-conditions,http://incytemi.com/pipeline/dermatology-and-iai-conditions,http://incyte.com/contact-us/other-locations,http://incyte.com/covid-19,http://incyte.com/what-we-do/portfolio/covid-19,http://headquarterlocations.com/delaware/incyte-corporation-headquarters-corporate-office,http://coronacures.co/incyte-announces-plans-to-initiate-a-phase-3-clinical-trial-of-ruxolitinib-jakafi-as-a-treatment-for-patients-with-covid-19-associated-cytokine-storm,http://incytempnqualityinitiatives.com/contact-us,http://hcp.jakafi.com/contact-us,http://incyte.com/contact-us/medical-information,http://cholangiocarcinoma.org/db/topic/an-open-label-safety-and-tolerability-study-of-incb062079-in-subjects,http://djph.org/wp-content/uploads/2021/07/djph-62-015.pdf,http://incyte.jp/contact-us/medical-information,http://clinicaltrials.gov/ct2/show/results/nct02752074,http://incytemi.com,http://ce.mayo.edu/content/incyte-virtual-exhibit-hall-hematology-review-2021,http://farmasiindustri.com/industri/list-of-pharmaceutical-manufacturer-in-united-states-of-america-part-4.html,http://incyte.com/contact-us,http://ce.mayo.edu/node/114978,http://ce.mayo.edu/content/incyte-virtual-exhibit-hall-19th-annual-mayo-clinic-hematology-review,http://wcgclinical.com/wp-content/uploads/2022/03/balancing-new-with-common-recruitment-tactics.pdf,http://bcan.org/clinicaltrials/incb099318-in-participants-with-advanced-solid-tumors,http://clinicaltrials.gov/show/nct04472429,http://ce.mayo.edu/node/110394,http://bcan.org/clinicaltrials/a-safety-and-tolerability-study-of-incagn02390-in-select-advanced-malignancies,http://bcan.org/clinicaltrials/arginase-inhibitor-incb001158-as-a-single-agent-and-in-combination-with-immune-checkpoint-therapy-in-patients-with-advanced-metastatic-solid-tumors,http://incytemi.com/get-support/contact-medical-information
robinw@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",89,personal,1,{f}{last},Robin,Weckesser,,"","","","",http://pbs.org/livelyhood/workday/trenches/trenchesdiaries.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
cindyg@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",89,personal,2,{f}{last},Cindy,Georgette,,"","","",+1 650 843 7364,http://histosearch.com/histonet/Nov01A/nosubject.html,http://histosearch.com/histonet/nov01a/nosubject.html,,,,,,,,,,,,,,,,,,,,,,,,,,,
dave.holland@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",88,personal,2,{f}{last},Dave,Holland,,,,,,http://ml.42.org/wmx/msg00395.html,http://ml.42.org/wmx/msg00358.html,,,,,,,,,,,,,,,,,,,,,,,,,,,
janetb@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",88,personal,2,{f}{last},Janet,Braisted,,"","","","",http://histosearch.com/histonet/nov01a/nosubject.html,http://histosearch.com/histonet/Nov01A/nosubject.html,,,,,,,,,,,,,,,,,,,,,,,,,,,
achadderton@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",87,personal,2,{f}{last},,,,,,,,http://flowcyt.cyto.purdue.edu/content/pucl-job1368-res-scientist-incyte-wilmington-de-041522,http://bioscope.org/content/pucl-job1368-res-scientist-incyte-wilmington-de-041522,,,,,,,,,,,,,,,,,,,,,,,,,,,
swee@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",87,personal,2,{f}{last},,,,,,,,http://bgscareerdevelopment.com/blog/page/25,http://bgscareerdevelopment.com/job-opening-at-incyte,,,,,,,,,,,,,,,,,,,,,,,,,,,
bdouty@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",87,personal,5,{f}{last},,,,,,,,http://rcsb.org/structure/2vew,http://rcsb.org/structure/2vex,http://rcsb.org/structure/2vey,http://rcsb.org/structure/2veu,http://rcsb.org/structure/2vev,,,,,,,,,,,,,,,,,,,,,,,,
epalmer@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",86,personal,4,{f}{last},,,,,,,,http://ce.mayo.edu/content/incyte-virtual-exhibit-hall-hematology-review-2021,http://ce.mayo.edu/content/incyte-virtual-exhibit-hall-19th-annual-mayo-clinic-hematology-review,http://ce.mayo.edu/node/114978,http://ce.mayo.edu/node/110394,,,,,,,,,,,,,,,,,,,,,,,,,
iberia@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",86,personal,2,{f}{last},,,,,,,,http://incyte.es,http://incyte.pt,,,,,,,,,,,,,,,,,,,,,,,,,,,
bfantasia@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",85,personal,2,{f}{last},,,,,,,,http://vcnp.net/author/piedmont,http://vcnp.net/category/uncategorized,,,,,,,,,,,,,,,,,,,,,,,,,,,
bl@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",85,generic,9,{f}{last},,,,,,,,http://forum.bestpractical.com/t/false-alarm-superuser-right-not-applied-to-members-of-group/1174,http://forum.bestpractical.com/t/superuser-right-not-applied-to-members-of-group/1173,http://forum.bestpractical.com/t/rfe-queue-groups/1172,http://github.com/perl/perl5/issues/125,http://github.com/perl/perl5/issues/169,http://openldap.org/lists/openldap-software/199910/msg00112.html,http://openldap.org/lists/openldap-software/199910/msg00103.html,http://openldap.org/lists/openldap-software/199912/msg00162.html,http://openldap.org/lists/openldap-software/199911/msg00055.html,,,,,,,,,,,,,,,,,,,,
aguntz@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",84,personal,1,{f}{last},,,,,,,,http://elclasificado.com/philadelphia/empleos/electricistas,,,,,,,,,,,,,,,,,,,,,,,,,,,,
xliu@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",84,personal,1,{f}{last},,,,,,,,http://aacrjournals.org/clincancerres/article/17/22/7127/76587/a-novel-kinase-inhibitor-incb28060-blocks-c-met,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ashea@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",84,personal,1,{f}{last},,,,,,,,http://cme.advocateaurorahealth.org/content/incyte-corporation,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ir@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",84,generic,6,{f}{last},,,,,,,,http://incyte.jp/about_incyte_japan,http://incyte.jp/contact-us,http://incyte.com/contact-us/other-locations,http://incyte.com/contact-us,http://incyte.com/contact-us.aspx,http://incyte.com/contactus,,,,,,,,,,,,,,,,,,,,,,,
hellobenelux@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",84,generic,6,{f}{last},,,Support,,,,,http://pharma.be/fr/a-propos-de-nous/membres,http://pharma.be/nl/over-ons/leden,http://pharma.be/fr/propos-de-nous/membres,http://ponatinib.nl,http://incyte.nl,http://pharma.be/fr/pharma-be/qui-est-pharma-be/nos-membres.html,,,,,,,,,,,,,,,,,,,,,,,
ychen@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",83,personal,1,{f}{last},,,,,,,,http://biomarkerres.biomedcentral.com/articles/10.1186/s40364-020-0184-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,
abarbour@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",83,personal,1,{f}{last},,,,,,,,http://vegfrinhibitors.com/itacitinib,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jdailey@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",83,personal,1,{f}{last},,,,,,,,http://phrma.org/-/media/project/phrma/phrma-org/phrma-refresh/certifications/compliance-officers-03-09-2023.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jimas@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",83,personal,1,{f}{last},,,,,,,,http://caldermpasociety.com/dinner-programs.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
incytegiving@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",83,personal,6,{f}{last},,,,,,,,http://incytegrantsandgiving.com/rms/default.aspx,http://incyte.jp/contact-us,http://incyte.com/contact-us/other-locations,http://incyte.com/contact-us,http://incyte.com/contact-us.aspx,http://incyte.com/contactus,,,,,,,,,,,,,,,,,,,,,,,
rkoch@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",82,personal,1,{f}{last},,,,,,,,http://onko-update.de/incyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,
pmurphy@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",82,personal,1,{f}{last},,,,,,,,http://appliancebyjon.com/how-to/scratch-and-dent-wilmington-de,,,,,,,,,,,,,,,,,,,,,,,,,,,,
medinfocanada@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",82,generic,7,{f}{last},,,,,,,,http://incytebiosciences.ca,http://incytebiosciences.ca/fr,http://incyte.com/contact-us/medical-information,http://incyte.com/contact-us,http://incyte.com/contact-us.aspx,http://incyte.com/contactus,http://incyte.com/contact-us/other-locations,,,,,,,,,,,,,,,,,,,,,,
jmorehead@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",82,personal,1,{f}{last},,,,,,,,http://ce.mayo.edu/node/116627,,,,,,,,,,,,,,,,,,,,,,,,,,,,
tstorti@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",81,personal,1,{f}{last},,,,,,,,http://mshofoundation.org/aws/msho/asset_manager/get_file/805131,,,,,,,,,,,,,,,,,,,,,,,,,,,,
khutson@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",81,personal,1,{f}{last},,,,,,,,http://cme.advocateaurorahealth.org/content/incyte-corporation,,,,,,,,,,,,,,,,,,,,,,,,,,,,
med_affairs_grants@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",81,generic,6,{f}{last},,,,,,,,http://incytegrantsandgiving.com/rms/default.aspx,http://incyte.jp/contact-us,http://incyte.com/contact-us/other-locations,http://incyte.com/contact-us,http://incyte.com/contact-us.aspx,http://incyte.com/contactus,,,,,,,,,,,,,,,,,,,,,,,
media@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",81,generic,8,{f}{last},,,Writing & communication,,,,,http://incyte.com/contact-us.aspx,http://incyte.com/contactus,http://incyte.com/contact-us/other-locations,http://incyte.com/contact-us,http://incyte.jp/about_incyte_japan,http://incyte.jp/contact-us,http://businesswire.com/news/home/20190315005537/en/company-profile-incyte-corporation,http://incyte.com/media/media-contact,,,,,,,,,,,,,,,,,,,,,
dfitzgerald@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",80,personal,1,{f}{last},,,,,,,,http://wppc-mddcva.org/boodle-time,,,,,,,,,,,,,,,,,,,,,,,,,,,,
lfeliz@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",80,personal,1,{f}{last},,,,,,,,http://ammf.org.uk/ammf-conference-2021/abstracts-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jpmedinfo@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",80,generic,7,{f}{last},,,Support,,,,,http://fpcr-joho.jp/search_list/index/genre:57,http://incyte.com/contact-us/medical-information,http://incyte.com/contact-us,http://incyte.com/contact-us.aspx,http://incyte.com/contactus,http://incyte.com/contact-us/other-locations,http://incyte.jp/contact-us,,,,,,,,,,,,,,,,,,,,,,
meetde@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",80,personal,6,{f}{last},,,,,,,,http://uncovervitiligo.com/de/impressum,http://meet-incyte.de/home/dgho-2022-wien,http://meet-incyte.de,http://meet-incyte.de/home/launchveranstaltung,http://meet-incyte.de/home/produkte-and-indikationen,http://meet-incyte.de/home/service-fur-sie,,,,,,,,,,,,,,,,,,,,,,,
forge@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,1,{f}{last},,,,,,,,http://ri.cmu.edu/pub_files/pub2/shamah_benjamin_1998_1/shamah_benjamin_1998_1.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_lux@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_uk@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_distribution@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
devopsmentoring@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,personal,1,{f}{last},,,,,,,,http://myccp.online/news/2023/05/health-care-and-life-sciences-mentorship-program,,,,,,,,,,,,,,,,,,,,,,,,,,,,
receptioneu@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,1,{f}{last},,,Writing & communication,,,,,http://incytegrantsandgiving.com/rms/default.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hkoblish@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,personal,5,{f}{last},,,,,,,,http://jitc.bmj.com/content/2/1/3.altmetrics,http://jitc.bmj.com/content/2/1/3,http://jitc.bmj.com/content/2/1/3.citation-tools,http://jitc.bmj.com/content/2/1/3.responses,http://jitc.bmj.com/content/2/1/3.share,,,,,,,,,,,,,,,,,,,,,,,,
hr@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,2,{f}{last},,,HR,,,,,http://incyte.com/culture-and-careers/open-positions,http://incyte.com/join-us/careers,,,,,,,,,,,,,,,,,,,,,,,,,,,
transparency@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,3,{f}{last},,,,,,,,http://incyte.com/responsibility/compliance-and-transparency,http://incyte.com/our-company/compliance-and-transparency,http://incyte.com/who-we-are/compliance-and-transparency,,,,,,,,,,,,,,,,,,,,,,,,,,
foundation@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,2,{f}{last},,,,,,,,http://incyte.com/culture-and-careers/incyte-involved,http://incyte.com/incyte-involved,,,,,,,,,,,,,,,,,,,,,,,,,,,
bd@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,generic,3,{f}{last},,,,,,,,http://incyte.jp/contact-us,http://incyte.com/what-we-do/collaborate-partners-in-science,http://incyte.com/contact-us,,,,,,,,,,,,,,,,,,,,,,,,,,
mma@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",79,personal,1,{f}{last},,,,,,,,http://reinberglab.com/current-present/past-students,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ra@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,generic,1,{f}{last},,,,,,,,http://ema.europa.eu:443/en/medicines/human/orphan-designations/eu-3-14-1424,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_fi@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_es@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_nl@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
lwu@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,personal,1,{f}{last},,,,,,,,http://peptidecost.com/incb054828,,,,,,,,,,,,,,,,,,,,,,,,,,,,
austria_contact@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,generic,3,{f}{last},,,Support,,,,,http://incyte.ch/en,http://incyte.ch/fr,http://incyte.ch,,,,,,,,,,,,,,,,,,,,,,,,,,
japan_clinicaltrials@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,personal,2,{f}{last},,,,,,,,http://fpcr-joho.jp/search_list/index/genre:57,http://clinicaltrials.gov/ct2/show/nct03910530,,,,,,,,,,,,,,,,,,,,,,,,,,,
employ@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,generic,1,{f}{last},,,,,,,,http://soaringbear.tripod.com/misc/jobhunt.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
uk_enquiries@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,generic,1,{f}{last},,,Writing & communication,,,,,http://incytebiosciences.uk,,,,,,,,,,,,,,,,,,,,,,,,,,,,
global_ists@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,personal,5,{f}{last},,,,,,,,http://incyteglobalmedicalinformation.com/legal-notices.aspx,http://incyteglobalmedicalinformation.com/search-clinical-trials-information.aspx,http://incyteglobalmedicalinformation.com/contact-us.aspx,http://incyteglobalmedicalinformation.com,http://incyteglobalmedicalinformation.com/report-adverse-event.aspx,,,,,,,,,,,,,,,,,,,,,,,,
qizhang@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,personal,4,{f}{last},,,,,,,,http://dmd.aspetjournals.org/content/early/2014/07/25/dmd.114.058883,http://dmd.aspetjournals.org/content/early/2017/03/10/dmd.116.074609,http://dmd.aspetjournals.org/content/early/2017/03/10/dmd.116.074609/tab-article-info,http://dmd.aspetjournals.org/content/early/2017/03/10/dmd.116.074609/tab-e-letters,,,,,,,,,,,,,,,,,,,,,,,,,
investor@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",78,generic,2,{f}{last},,,Finance,,,,,http://thelabrat.com/jobs/companies/incyte.shtml,http://thelabrat.com/jobs/companies/Incyte.shtml,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_denmark@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_norway@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
supplier@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,generic,5,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/global-purchase-order-terms-conditions.pdf,http://incyte.com/portals/0/assets/supplier/japan-purchase-order-terms-conditions.pdf,http://incyte.com/portals/0/assets/supplier/shanghai-purchase-order-terms-conditions.pdf,http://incyte.com/suppliers/prospective-suppliers,http://incyte.com/suppliers/supplier-diversity,,,,,,,,,,,,,,,,,,,,,,,,
gmaoperations@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,personal,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/compliance%20and%20transparency/global_policy%20on%20expanded%20access_compassionate%20use.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
pharmafr@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,personal,2,{f}{last},,,,,,,,http://incyte.fr/pdf/donnees-personnelles.pdf,http://incyte.fr/pdf/mentions-legales.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,
outreach@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,generic,1,{f}{last},,,,,,,,http://incytegrantsandgiving.com/rms/default.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,
thenordicgrant@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,personal,2,{f}{last},,,,,,,,http://grant.incytenordics.eu/previous-winners,http://grant.incytenordics.eu/privacy-policy,,,,,,,,,,,,,,,,,,,,,,,,,,,
incytequality@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,generic,1,{f}{last},,,,,,,,http://incytempnqualityinitiatives.com,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kcuca@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,personal,1,{f}{last},,,,,,,,http://businesswire.com/news/home/20210223005942/es,,,,,,,,,,,,,,,,,,,,,,,,,,,,
lpechinski@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,personal,1,{f}{last},,,,,,,,http://cme.advocateaurorahealth.org/content/incyte-corporation,,,,,,,,,,,,,,,,,,,,,,,,,,,,
facilitieseu@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,personal,2,{f}{last},,,,,,,,http://penthalaz.ch/telechargements-a/doc_download/2660-guide-mobilit%c3%a9-pour-les-entreprises-et-institutions.html,http://news-med.com/index.php/annuaire/viewadresse/fr/26/24/34019,,,,,,,,,,,,,,,,,,,,,,,,,,,
careers@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",77,generic,2,{f}{last},,,HR,,,,,http://thelabrat.com/jobs/companies/incyte.shtml,http://thelabrat.com/jobs/companies/Incyte.shtml,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_fr@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ap@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_at@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_ch@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
auditcommittee@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/compliance%20and%20transparency/incyte-code-of-business-conduct.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
us_iir@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,personal,1,{f}{last},,,,,,,,http://incyte.com/what-we-do/pharmaceutical-portfolio,,,,,,,,,,,,,,,,,,,,,,,,,,,,
web@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,generic,1,{f}{last},,,,,,,,http://browniesauto.com/susan-snodgrass-incyte/48202216,,,,,,,,,,,,,,,,,,,,,,,,,,,,
recruiting@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,generic,2,{f}{last},,,HR,,,,,http://incyte.com/culture-and-careers/open-positions,http://incyte.com/join-us/careers,,,,,,,,,,,,,,,,,,,,,,,,,,,
sparasuraman@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,personal,2,{f}{last},,,,,,,,http://ehoonline.biomedcentral.com/articles/10.1186/s40164-016-0031-8,http://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4422-6,,,,,,,,,,,,,,,,,,,,,,,,,,,
incytecanadainquiry@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,generic,4,{f}{last},,,,,,,,http://incyte.com/contact-us/locations,http://incytebiosciences.ca,http://incytebiosciences.ca/fr,http://incyte.com/contact-us/headquarters,,,,,,,,,,,,,,,,,,,,,,,,,
skanthala@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,personal,2,{f}{last},,,,,,,,http://ashpublications.org/bloodadvances/article/4/8/1656/454448/a-phase-1-trial-of-itacitinib-a-selective-jak1,http://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2020004823/452638/ruxolitinib-for-the-treatment-of-steroid,,,,,,,,,,,,,,,,,,,,,,,,,,,
shlee@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",76,personal,2,{f}{last},,,,,,,,http://histosearch.com/histonet/Jan01A/RE.Questions...html,http://histosearch.com/histonet/Jan01A/Questions...html,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_de@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_it@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_tec@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
accounts_payable_se@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,generic,1,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/supplier/non-ariba-network-suppliers-invoicing-instructions.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
compliance@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,generic,2,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/compliance%20and%20transparency/global_policy%20on%20expanded%20access_compassionate%20use.pdf,http://incyte.com/portals/0/assets/compliance%20and%20transparency/incyte-code-of-business-conduct.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,
global_iir@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,personal,1,{f}{last},,,,,,,,http://incyte.com/what-we-do/pharmaceutical-portfolio,,,,,,,,,,,,,,,,,,,,,,,,,,,,
lrobinsonclanton@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,personal,1,{f}{last},,,,,,,,http://pcapna.enpnetwork.com/nurse-practitioner-events/140499-real-world-case-discussion-intervene-with-jakafi-ruxolitinib,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sales@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,generic,1,{f}{last},,,Sales,,,,,http://biobank.co.kr/maker/hhh/hexagen.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
incyte_italy_contact@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,generic,1,{f}{last},,,Support,,,,,http://incyte.it,,,,,,,,,,,,,,,,,,,,,,,,,,,,
globalresponsibility@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,generic,2,{f}{last},,,,,,,,http://incyte.com/portals/0/assets/responsibility%20pdfs/global_responsibility_report_2022.pdf,http://incyte.com/responsibility,,,,,,,,,,,,,,,,,,,,,,,,,,,
dgryska@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",75,personal,3,{f}{last},,,,,,,,http://biospace.com/article/releases/incyte-announces-proposed-public-offering-of-4-945-000-shares-of-common-stock-,http://businesswire.com/news/home/20170908005432/en/incyte-announces-pricing-public-offering-4945000-shares,http://businesswire.com/news/home/20170907006713/en/incyte-announces-proposed-public-offering-4945000-shares,,,,,,,,,,,,,,,,,,,,,,,,,,
msandell@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",69,personal,0,{f}{last},Maura,Sandell,,Therapeutic Specialist,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
rscherber@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",69,personal,0,{f}{last},Robyn,Scherber,Management,Senior Director,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
layala@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",69,personal,0,{f}{last},Lauren,Ayala,Writing & communication,Senior Director Investor Relations,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hberger@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",68,personal,0,{f}{last},Hebe,Berger,,Team Captain,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
bcroce@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",68,personal,0,{f}{last},Bonnie,Croce,HR,Human Resources Department,"","",+1 302 425 2704,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jizzo@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",67,personal,0,{f}{last},Joseph,Izzo,,"","","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
pfrandsen@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",67,personal,0,{f}{last},Peter,Frandsen,Sales,Sales Marketing Director,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jtrudel@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",67,personal,0,{f}{last},Jeff,Trudel,,"","","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
vturano@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",66,personal,0,{f}{last},Vince,Turano,,"","","",+1 516 359 2414,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
nfoschi@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",66,personal,0,{f}{last},Nick,Foschi,HR,Director Human Resources,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jliao@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",65,personal,0,{f}{last},Jason,Liao,Management,Office Manager,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jknudsvig@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",65,personal,0,{f}{last},Julie,Knudsvig,Sales,Sales Representative,"","",+1 612 850 1551,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
marketaccess@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",64,generic,0,{f}{last},,,Sales,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ykim@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",64,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jdoria@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",63,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hflach@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",62,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mmarkhauser@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",61,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
zgao@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",60,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mantonelli@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",17,personal,0,{f}{last},Michelle,Antonelli,,"","","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hreurope@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",14,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
leye@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",14,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
incyte_tradeanddistribution@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",13,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mhall@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",12,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sshort@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",11,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
rgreen@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
snanitacastillo@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
bnewton@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
skawaguchi@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
janconacci@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
clove@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
chou@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
rosullivan@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
incyteeusupplychain@incyte.com,incyte.com,Incyte,US,DE,Delaware,19803,"",10,personal,0,{f}{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
